Cargando…

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)

Background: In people with overweight or obesity, long-term maintenance of weight loss is challenging. Subcutaneous (s.c.) semaglutide, a glucagon-like peptide-1 analogue, has shown clinically-relevant weight loss in a phase 2 trial in people with obesity. STEP 4 investigated the impact of continued...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rubino, Domenica M, Abrahamsson, Niclas, Davies, Melanie, Hesse, Dan, Greenway, Frank L, Jensen, Camilla, Lingvay, Ildiko, Mosenzon, Ofri, Rosenstock, Julio, Rubio, Miguel A, Rudofsky, Gottfried, Tadayon, Sayeh, Wadden, Thomas A, Dicker, Dror
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Adipose Tissue, Appetite, and Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089318/ http://dx.doi.org/10.1210/jendso/bvab048.129

Ejemplares similares

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
por: Wharton, Sean, et al.
Publicado: (2021)

Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management
por: Enebo, Lone B, et al.
Publicado: (2021)

Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study
por: Wilding, John P H, et al.
Publicado: (2021)

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
por: Kushner, Robert F., et al.
Publicado: (2020)

Preclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity
por: John, Linu M, et al.
Publicado: (2021)

MON-120 Effect of Weight Loss on Physical Function Measured by the 6-Minute Walking Distance Test in Individuals with Obesity: Results from the SCALE IBT Trial of Liraglutide 3.0 Mg
por: Rubino, Domenica, et al.
Publicado: (2019)

SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial
por: Wadden, Thomas, et al.
Publicado: (2019)

SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

OR10-3 Long-term Weight Loss Maintenance with Obesity Pharmacotherapy: a 5-Year Retrospective Study
por: Andre, Clarissa, et al.
Publicado: (2022)

Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial
por: Fox, Claudia K, et al.
Publicado: (2021)

RF24 | PSUN116 Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS
por: Jensterle, Mojca, et al.
Publicado: (2022)

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)
por: Suresh, Swaroop H, et al.
Publicado: (2022)

OR23-3 Hunger Hormone Asprosin Activates Orexigenic Neurons via SK Currents
por: Feng, Bing, et al.
Publicado: (2022)

SAT654 Regulation Of The Melanocortin-4 Receptor (mc4r) By Attractin Like Protein 1 (alp1)
por: Buscaglia, Paul, et al.
Publicado: (2023)

OR10-4 Sex as an Independent Variable in Satiety
por: Acosta, Andres, et al.
Publicado: (2022)

Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)
por: Rahman, Syed Kasfur, et al.
Publicado: (2022)

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
por: Mosenzon, Ofri, et al.
Publicado: (2022)

OR12-4 Adipocyte Subpopulations Mediate Obesity-Associated Inflammation in Adipose Tissues
por: Luong, Quyen, et al.
Publicado: (2019)

SAT-598 Shared Signaling Profile Between Human MRAPα-Induced Human MC4R Constitutive Activity and Obesity-Associated Human MC4R Constitutive Activity
por: Botha, Rikus, et al.
Publicado: (2020)

Laminin-α4 Is Uniquely Upregulated in Subcutaneous White Adipose Tissue in Murine and Human Models of Obesity
por: Goddi, Anna, et al.
Publicado: (2021)

Distinct Calcium Signaling for Wildtype, Loss-of-Function and Gain-of-Function Human MC4R Variants
por: Kumar, Shree S, et al.
Publicado: (2021)

OR04-01 MRAP2 Regulates Energy Homeostasis by Promoting Primary Cilia Localization of MC4R
por: Bernard, Adelaide A, et al.
Publicado: (2020)

OR23-4 Intestinal FFA2 and FFA3 Mediate Obesogenic Effects in Mice on a Western Diet
por: Gough, Sophie, et al.
Publicado: (2022)

FRI048 Cardiometabolic Risk Markers In Children With Obesity And Variants In MC4R Pathway Related Genes
por: Salama, Mostafa, et al.
Publicado: (2023)

PSUN97 Regulation of melanocortin-3 and -4 receptors by isoforms of melanocortin-2 receptor accessory protein 1 and 2
por: Ji, Ren-Lei, et al.
Publicado: (2022)

OR01-4 Mast Cells and Human Adipose Beiging: Mast Cells Are Recruited to Subcutaneous White Adipose and Degranulate in Response to Cold
por: Kern, Philip, et al.
Publicado: (2019)

Timing of Onset of Adverse Events With Setmelanotide, an MC4R Agonist, in Patients With Severe Obesity Due to LEPR or POMC Deficiency
por: Clément, Karine, et al.
Publicado: (2021)

OR20-4 NMRI-metabolomics Variables Associated With The Metabolically-healthy Obese Phenotype And The Transitions Between Metabolically-healthy And Unhealthy Obesity Phenotypes.
por: Vargas-Vazquez, Arsenio, et al.
Publicado: (2019)

LBODP003 Effects Of 4-weeks’ Treatment With Intraperitoneal Colchicine On Metabolic And Inflammatory Outcomes In Mice Fed A High-fat Diet
por: Arner, Brooke E, et al.
Publicado: (2022)

OR10-02 Effect Of Phosphodiesterase 4 Inhibitors On Weight Loss And Energy Homeostasis In Mice With Obesity Induced By A High-fat-diet
por: de Andrade, Maria Amelia A M, et al.
Publicado: (2023)

FRI047 Clinical Characteristics Of Patients With Morbid Obesity With Semaphorines (SEMA3D,E,G) And PLXNA3&4 Gene Variants
por: Berra, Maddie, et al.
Publicado: (2023)

MON-112 Gelesis100 Reduces Insulin Resistance in Patients Who Are Overweight or Have Obesity with High Insulin Resistance: Results of the GLOW Study
por: Greenway, Frank, et al.
Publicado: (2019)

Insulin Resistance Moderates the Association Between BMI and Metabolic Syndrome Severity in Women 4–10 Years After Pregnancy, Independent of Gestational Diabetes Status
por: Callahan, Makenzie, et al.
Publicado: (2021)

A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide
por: Haws, Robert, et al.
Publicado: (2021)

SAT-LB023 Elevated Fasting Plasma Glucose Predicts Higher Odds For Becoming A Super-responder With Gelesis100 In The GLOW Pivotal Weight-loss Study
por: Greenway, Frank, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o6ju122fd8v827gljeh3taj76g